Nevertheless, a number of recent studies have identified heterogeneity in lineage program and differentiation state, both among genetically diverse tumors and within genetically homogeneous populations of cells, to be associated with variability in tumor cells’ sensitivity to BRAF and MEK inhibitors [5,35,43,44,45,46]. This evidence concerns the gene BRAF and neoplasm.